Last reviewed · How we verify
DongE E Jiao Coporation Limited — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Wuzi Yanzong oral liquid | Wuzi Yanzong oral liquid | marketed | Reproductive Health / Traditional Chinese Medicine | |||
| Guilu Erxian Oral Liquid | Guilu Erxian Oral Liquid | marketed | Traditional Chinese Medicine / General Wellness | |||
| compound E Jiao Jiang(cEJJ) | compound E Jiao Jiang(cEJJ) | marketed | Traditional Chinese Medicine / Hematology |
Therapeutic area mix
- Reproductive Health / Traditional Chinese Medicine · 1
- Traditional Chinese Medicine / General Wellness · 1
- Traditional Chinese Medicine / Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for DongE E Jiao Coporation Limited:
- DongE E Jiao Coporation Limited pipeline updates — RSS
- DongE E Jiao Coporation Limited pipeline updates — Atom
- DongE E Jiao Coporation Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). DongE E Jiao Coporation Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/donge-e-jiao-coporation-limited. Accessed 2026-05-17.